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INTRODUCTION
The prognosis of children with acute myeloid leukemia
(AML) has improved over the past 30 yr (1). Reported sur-
vival figures range from 40 to 60%, and the proportion of
patients achieving complete remission (CR) range from 70 to
90% (2-6). This success reflects the use of increasingly inten-
sive induction chemotherapy followed by post-remission che-
motherapy or allogeneic hematopoietic stem cell transplan-
tation (HSCT). However, debate continues regarding the best
chemotherapeutic regimen in induction and post-remission
therapy. The most widely used combination of chemothera-
py for AML is anthracycline and cytarabine (ara-C), often in
combination with etoposide or 6-thioguanine (6-TG) (2-6). 
Cytarabine is a major antimetabolic drug used in the treat-
ment of AML. However, the drug is rapidly inactivated by
cytidine deaminase, and has a very short plasma half-life (7).
Many studies have been done on the administration sched-
ule and dose of cytarabine in order to achieve optimum ther-
apeutic effect with minimal adverse events. Other trials for
overcoming the limitation of cytarabines include the devel-
opment of cytarabine derivatives resistant to deamination (7).
N4-behenoyl-1-b-D-arabinofuranosylcytosine (BHAC) is
lipophilic, resistant to cytidine deaminase, and has strong
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Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares
Favorably with Idarubicin Plus Cytarabine-based Regimen for Children
with Previously Untreated Acute Myeloid Leukemia: 10-Year 
Retrospective, Multicenter Study in Korea 
We investigated the outcome of idarubicin plus N
4-behenoyl-1-b-D-arabinofuranosyl
cytosine (BHAC)-based chemotherapy (BHAC group, n=149) compared to idaru-
bicin plus cytarabine-based chemotherapy (cytarabine group, n=191) for childhood
acute myeloid leukemia (AML). Between January 1996 and December 2005, 340
children with AML from 5 university hospitals in Korea received the BHAC-based
or cytarabine-based chemotherapy, with or without hematopoietic stem cell trans-
plantation. After induction therapy, 264 (77.6%) of 340 children achieved a complete
remission (CR) and 43 (12%) achieved a partial remission (PR). The CR rate in the
BHAC group was higher than in the cytarabine group (85.2% vs. 71.7%, P=0.004).
However, the overall response rate (CR+PR) was not different between the two
groups (93.3% vs. 87.9%, P=0.139). The 5-yr estimates of overall survival (OS) of
children in the two groups were similar (54.9% for the BHAC group vs. 52.4% for
the cytarabine group, P=0.281). Although the results were analyzed according to
the treatment type and cytogenetic risk, the OS showed no significant difference
between the BHAC group and the cytarabine group. In the present study, the clini-
cal outcomes of the BHAC-based chemotherapy, consisting of BHAC, idarubicin,
and 6-TG, are comparable to that of the cytarabine-based chemotherapy for child-
hood AML.
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less of administration schedules (8-10). 
In clinical studies, BHAC combined with anthracycline
showed a 60-80% CR rate, which was comparable to cytara-
bine-based chemotherapy for adult AML (11-14). Idarubicin
(IDA)-BHAC combination regimen, which consists of IDA
plus BHAC and 6-TG, has been widely used for induction
or post-remission therapy for childhood AML in Korea. How-
ever, few reports have been made on IDA-BHAC chemother-
apy for childhood AML (13, 15). In this retrospective, mul-
ticenter study, we report the results of IDA plus BHAC-based
chemotherapy for childhood AML between 1996 and 2005.
It is well established that multi-drug combination chemother-
apy including cytarabine combined with anthracycline has
shown a high CR rate and has been widely used in consolida-
tion therapy as well as induction therapy for childhood AML
(2-6). Therefore, we investigated the outcomes of BHAC-
based chemotherapy compared to the cytarabine-based che-
motherapy for childhood AML. 
MATERIALS AND METHODS
Patients
Between January 1996 and December 2005, 464 children
from 5 university hospitals in Korea were diagnosed with
AML. Patients included were younger than 20 yr at the time
of diagnosis and had no prior treatment. Patients with Down
syndrome, secondary AML, extramedullary leukemia with-
out bone marrow involvement, or acute promyelocytic leu-
kemia were excluded. Patients who underwent HLA-mis-
matched HSCT or cord blood transplantation after remission
were also excluded. If the number of patients treated with
each chemotherapy protocol was below 30, the data from the
corresponding institution were not included. A total of 340
children were included in this study.
Diagnosis
Initial diagnosis of AML was done at each hospital. Leu-
kemia subtypes were recorded using the French-American-
British (FAB) classification system (16). Bone marrow was
analyzed for cytogenetic abnormalities and immunopheno-
type at diagnosis.
Treatment 
The IDA plus BHAC-based induction regimen consisted
of BHAC daily 200-250 mg/m2 intravenously (IV) for 7 con-
secutive days, IDA daily 12 mg/m2 IV 3 consecutive days (day
1 to 3), and 6-TG daily 100 mg/m2orally for 7 days. The IDA
plus cytarabine-based induction regimen consisted of cytara-
bine daily 100 mg/m2 continuously IV for 7 days or 100 mg/
m2/12-hr b.i.d IV infusion for 7 days and IDA daily 12 mg/
m2 IV 3 consecutive days (day 1 to 3). According to the each
institutional principle, etoposide daily 150 mg/m2 IV for 3
days (day 4 to 6) and 6-TG daily 160 mg/m2 orally for 7 days
were added in the IDA plus cytarabine-based induction che-
motherapy.
Patients who had achieved a CR received consolidation
therapy. Allogeneic HSCT was recommended to all patients
in first remission with HLA-matched familial or unrelated
donors. HLA typing for class I and class II antigens was per-
formed using standard serologic techniques. Familial donor-
patient pairs were considered fully matched by compatibili-
ty for HLA-A, -B, -C, and -DRB1. Unrelated donor-patient
pairs were considered matched for HLA-A, -B, and -DRB1.
The patients without an available donor received autologous
HSCT or further intensive chemotherapy in accordance with
the institutional principle. Patients who had not achieved
remission received another course of chemotherapy. For con-
venience, treatment was subdivided into two groups as fol-
lows: the patients who underwent HSCT after induction ther-
apy (Transplantation group) and the patients who did not
receive HSCT (Chemotherapy group), including patients who
died during induction chemotherapy or patients lacking an
available donor.
In post-remission chemotherapy, each institution adopted
a different chemotherapy protocol. Therefore, patients were
classified into the ‘‘BHAC group’’ or the ‘‘cytarabine group’’
in accordance with the regimen administered for remission
induction. 
Definitions and statistics 
CR was defined as less than 5% leukemic blasts in the bone
marrow with evidence of normal hematopoiesis, no leukemia
cells in peripheral blood or anywhere else. Induction death
was defined as a fatal event occurring within the first 6 weeks
of treatment. Induction death occurring before starting treat-
ment was not included in this study. Partial remission (PR)
was defined as a bone marrow with 5-15% blast cells and evi-
dence of regeneration of normal hematopoietic cells. Patients
who did not achieve CR or PR and who survived after the first
6 weeks of treatment were defined as nonresponders (NR).
Cytogenetic abnormalities were classified into 3 risk groups:
low risk, t(8;21), inv(16); high risk, 11q23 rearrangement,
-5, del(5q), -7, del(7q), inv(3)/t(3;3)/ins(3;3); intermediate
risk, normal karyotype or other numerical or structural abnor-
malities.
Event-free survival (EFS) was calculated from the date of
diagnosis to last follow-up or first event (failure to achieve
remission, demonstration of resistant leukemia, relapse, sec-
ond malignancy or death due to any cause, whichever occurr-
ed first). Patients who did not attain CR were considered fail-
ures at time zero. Overall survival (OS) was defined as the
time between diagnosis and death from any cause or time of
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The characteristics of two chemotherapy groups were com-
pared using chi-square test or Fischer’s exact test for categori-
cal data and Mann-Whitney U test for continuous variables.
Probabilities of survival were estimated using the Kaplan-
Meier method and were compared using the log-rank test.
Data for all surviving patients were censored as of April 2007. 
RESULTS
Patients characteristics
Patient characteristics of the two groups are given in Table
1. A total of 340 patients were included in the BHAC group
and the cytarabine group. There was no significant difference
in the patient characteristics between the two groups. The
median age at presentation was 7.7 yr, 7% were infants less
than 1 yr of age, 34% were 10-yr old or more at diagnosis.
The median white blood cell count (WBC) at diagnosis was
15.8×109/L, and 25% of the children showed a WBC count
of at least 50×109/L. Karyotypes were available for 92% of
patients. The cytogenetics of patients in the two groups are
presented in Table 2. A significant difference was noted with
regards to the frequency of cytogenetic aberrations (P=0.03),
with patients with the 11q23 rearrangement more frequently
observed in the BHAC group than in the cytarabine group.
In the cytarabine group, the different induction regimens were
administered equally. HSCT was performed in 211 patients
(62%) treated in both groups. 
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Characteristics
Parameters
BHAC 
group
Cytarabine
group
P value*
Number of patients 149 191
Median age, yr (range) 7.7 (0-17.2) 7.7 (0-18.9) NS
Male/female, n 86/63 105/86 NS
FAB type, n (%) 0.009
M0/M1 18 (12.1) 48 (25.1)
M2 60 (40.3) 74 (38.7)
M4/M5 52 (34.9) 44 (23.0)
M6/M7/others 19 (12.8) 25 (13.1)
WBC at diagnosis (×10
9/L)
Median 15.9 15.8 NS
Cytogenetic group, n (%) 0.03
Low 39 (26.2) 54 (28.3)
Intermediate 80 (53.7) 101 (52.9)
High 24 (16.1) 15 (7.9)
Unknown 6 (4.0) 21 (11.0)
Induction regimen, n (%)
IDA+BHAC+TG 149 (100)
IDA+Cytarabine 65 (34.0)
IDA+Cytarabine+VP 64 (33.5)
IDA+Cytarabine+VP+TG 62 (32.5)
Treatment, n (%) NS
Chemotherapy 57 (38.7) 72 (37.7)
Transplantation 92 (61.7) 119 (62.3)
Type of transplantation, n (%) <0.001
Familial donor HSCT 22 (14.8) 53 (27.8)
Unrelated donor HSCT 28 (18.7) 54 (28.2)
Autologous HSCT 42 (28.2) 14 (7.3)
Table 1. Patient characteristics
BHAC 
group
No. %
Cytarabine
group
No. %
Total
No. %
Number of patients 149 191 340
Low
t(8;21) 36 24.2 47 24.6 83 24.4
inv(16) 3 2.0 7 3.7 10 2.9
Intermediate
Normal 42 28.2 52 27.2 94 27.6
Others 38 25.5 49 25.7 87 25.6
High
11q23 abnormality 18 12.1 8 4.2 26 7.6
-5/del(5q) 0 0.0 2 1.0 2 0.6
-7/del(7q) 5 3.4 5 2.6 10 2.9
inv(3)/t(3;3)/ins(3;3) 1 0.7 0 0.0 1 0.3
Unknown 6 4.0 21 11.0 27 7.9
Table 2. Details of cytogenetics  
*Comparison between the BHAC group and Cytarabine group.
CR, complete remission; PR, partial remission; NR, nonresponder; BHAC, N
4-behenoyl-1-b-D-arabinofuranosyl cytosine; NS, not significant.
BHAC group
No. %
Cytarabine group
No. %
Total
P value*
No. %
Number of patients 149 191 340
CR 127 85.2 137 71.7 264 77.6 0.004
PR 12 8.1 31 16.2 43 12.6 0.03
NR 6 4.0 9 4.7 15 4.4 NS
Induction death 4 2.7 14 7.3 18 5.3 NS
Response (CR+PR) 139 93.3 168 87.9 307 90.3 NS
Table 3. Results of induction therapy in the BHAC and the Cytarabine group 
BHAC, N
4-behenoyl-1-b-D-arabinofuranosyl cytosine. 
*Comparison between the BHAC group and Cytarabine group.
M, male; F, female; FAB, French-American-British; WBC, white blood
cell count; IDA, idarubicin; BHAC, N
4-behenoyl-1-b-D-arabinofuranosyl
cytosine; TG, 6-thioguanine; VP, etoposide; HSCT, hematopoietic stem
cell transplantation; NS, not significant.
ParametersResponse to induction treatment and survival
After induction chemotherapy, 264 (77.6%) of 340 chil-
dren achieved a CR. The results of the BHAC group and the
cytarabine group are compared in Table 3. The CR rate in
the BHAC group was higher than in the cytarabine group
(85.2% vs. 71.7%, P=0.004). However, the overall response
(CR+PR) rates between the 2 groups were not significantly
different (93.3% vs. 87.9%, P=0.139). The percentage of
induction death and nonresponders showed no significant
difference between the two groups. Five (33%) of 15 nonre-
sponders after the first induction therapy in the two groups
were alive at time of last follow-up. In the cytarabine group,
the overall response rates of the three types of induction reg-
imen (IDA+cytarabine, IDA+cytarabine+etoposide, and
IDA+cytarabine+etoposide+6-TG) were 78.5%, 93.8%,
and 91.9%, respectively (P=0.022).
A total of 200 patients survived with a median follow-up
of 4.1 yr. The 5-yr estimate of OS of 340 children was 53.3%.
The 5-yr estimates of OS of children were not significantly
different between the BHAC group and the cytarabine group
(54.9% vs. 52.4%, P=0.281) (Fig. 1). Although the children
were divided into the two groups (chemotherapy group and
transplantation group), the OS and EFS showed no signifi-
cant difference between the BHAC group and the cytarabine
group (Fig. 2, 3). When the patients who died during induc-
tion chemotherapy were excluded in the chemotherapy group,
a total of 111 patients received the further intensive chemo-
therapy. The 5-yr estimates of OS of the 111 children in the
BHAC group and cytarabine group were 44.6% and 38.6%,
respectively (P=0.591) and the EFS were 29.8% and 28.6%,
respectively (P=0.679). For patients who received HSCT, the
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Fig. 1. Kaplan-Meier estimates of OS at 5 yr for the 340 children. 
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Fig. 2. Kaplan-Meier estimates of OS of children without HSCT (A) and with HSCT (B) at 5 yr. 
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Fig. 3. Kaplan-Meier estimates of EFS of children without HSCT (A) and with HSCT (B) at 5 yr. 
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BOS and EFS of children in the two groups were similar with
regard to the type of HSCT (Table 4). The OS of patients in
the two groups was also not significantly different in terms
of the cytogenetic risk (Table 5).
The 5-yr estimates of OS and EFS of patients achieving a
first CR were higher in the transplantation group (64.4%
and 58.0%, respectively) than in the chemotherapy group
(41.0% and 28.6%, respectively) (P<0.001).
DISCUSSION
In the present study, the clinical outcome of the BHAC-
based regimen, consisting of BHAC, idarubicin, and 6-TG,
are comparable to that of the cytarabine-based regimen for
childhood AML. In a phase II study, BHAC monotherapy for
adult AML produced a 36% CR rate and adverse events such
as nausea and vomiting were less than for cytarabine (17). In
a comparative study between BHAC and cytarabine in com-
bination induction and consolidation therapy for adults with
de novo AML, the efficacy of BHAC given with daunorubicin
was found to be inferior to that of cytarabine in combination
with daunorubicin (14). However, the dose of BHAC was not
equivalent to that of cytarabine in terms of the mean leuko-
cyte nadir of both groups (18). In Korea, the combination
regimen consisting of IDA and BHAC has been widely used
for induction or post-remission therapy for adult and child-
hood AML since 1996. Park et al. (13) reported that IDA-
BHAC combination regimen for previously untreated adult
and childhood AML showed a high CR rate (75%), which
was similar or superior to results obtained with cytarabine
and other anthracyclines. However, a small number of chil-
dren (22%) were included in their study and follow-up dura-
tion was too short to draw a complete conclusion.
The anti-leukemic efficacy of IDA-BHAC regimen in remis-
sion induction appears to be effective, with a high CR rate
(85.2%) compared to the CR rate (71.7%) of cytarabine-based
regimen in our study. The proportion of NR is comparable
between the 2 groups after remission induction chemother-
apy (4% in the BHAC group; 4.7% in the cytarabine group).
In the present study, children in the two groups have a sim-
ilar 5-yr estimate of OS (55% in the BHAC group; 53% in
the cytarabine group). These results are comparable to pre-
viously summarized results of the AML-BFM93, UK-MRC
AML10, CCG-2891, and NOPHO-AML93, which enroll-
ed patients between 1988 and 2001 (2-4, 6). Children with
de novo AML in these studies showed CR rates of 78-93%,
induction death rates of 2-7%, proportion of NR of 3-18%,
and 5-yr estimates of OS of 47-66%. The addition of other
agents to the standard ‘‘7+3’’ induction regimen did not im-
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*Comparison between the BHAC group and Cytarabine group.
EFS, event-free survival; OS, overall survival; BHAC, N
4-behenoyl-1-b-
D-arabinofuranosyl cytosine; HSCT, hematopoietic stem cell transplan-
tation; s.e., standard error; NS, not significant.
BHAC 
group
Cytarabine
group
P value*
Number of patients 149 191
EFS at 5 yr, % (s.e.) NS
Familial donor HSCT 77.3 (8.9) 54.4 (7.2)
Unrelated donor HSCT 59.1 (9.6) 60.3 (6.8)
Autologous HSCT 48.5 (7.8) 57.1 (13.2)
OS at 5 yr, % (s.e.) NS
Familial donor HSCT 74.7 (10.0) 62.6 (7.6)
Unrelated donor HSCT 61.6 (9.8) 69.8 (6.3)
Autologous HSCT 59.2 (8.8) 64.3 (12.8)
Table 4. Results of HSCT in the BHAC and the Cytarabine group
BHAC group
No. OS, % (s.e.)
Total
No. OS, % (s.e.)
Cytarabine group
No. OS, % (s.e.)
Number of patients 149 191 340
Low 39 63.0 (9.3) 54 64.5 (6.8) 93 63.0 (5.7)
t(8;21) 36 59.1 (10.0) 47 66.0 (7.2) 83 62.2 (6.2)
inv(16) 3 100.0 (0.0) 7 57.1 (18.7) 10 70.0 (14.5)
Intermediate 80 53.9 (6.0) 101 52.3 (5.4) 181 52.8 (4.0)
Normal 42 60.2 (8.0) 52 60.3 (7.6) 94 60.2 (5.5)
Others 38 46.9 (8.7) 49 44.4 (7.4) 87 45.3 (5.6)
High 24 34.0 (14.0) 15 17.6 (14.1) 39 26.7 (10.3)
11q23 abnormality 18 45.8 (15.8) 8 16.7 (14.8) 26 34.9 (12.8)
-5/del(5q) 0 NA 2 100 (0.0) 2 100 (0.0)
-7/del(7q) 5 0.0 (0.0) 5 0.0 (0.0) 10 0.0 (0.0)
inv(3)/t(3;3)/ins(3;3) 1 0.0 (0.0) 0 NA 1 0.0 (0.0)
Unknown 6 100.0 21 51.7 (11.9) 27 63.8 (9.8)
Table 5. Probability of 5-yr OS by cytogenetic prognostic group at diagnosis 
The OS of children in the two groups were not significantly different in regard to the cytogenetic risk.
OS, overall survival; NA, not applicable; s.e., standard error; BHAC, N
4-behenoyl-1-b-D-arabinofuranosyl cytosine.
Parameters
Parametersprove the remission rate, OS or EFS in children and adoles-
cents with AML in UK-MRC AML10 trial and CCG-213
study (2, 3). In our results, the addition of etoposide improves
the remission rate. However, children who received the three
types of induction regimen have shown similar long-term
outcome in terms of OS and EFS.
Since the cytotoxic effect of cytarabine is time-dependent
and S-phase specific, the standard dose of cytarabine is thought
to have better therapeutic effects when administered by con-
tinuous IV infusions rather than by short-time IV infusion
(7). Because BHAC, a new cytarabine analogue, has a long
plasma half-life after IV administration and releases cytara-
bine slowly, it may give the same effect as continuous cytara-
bine infusion (19). Studies of Nara et al. (10) have demon-
strated that BHAC is rapidly taken into leukemic blasts and
converted to cytarabine, and has a suppressive activity on
self-renewal of leukemic blast progenitors in vitro. There-
fore, BHAC may contribute to these results which are com-
parable to those of cytarabine-based chemotherapy.
In our study, the 5-yr estimates of EFS and OS for children
appear to be much lower in the chemotherapy group than
in the transplantation group. In this retrospective survey, the
chemotherapy group includes induction deaths and has more
nonresponders than the transplantation group. Although
autologous and allogeneic HSCT represent approaches to
dose intensification, several randomized studies in pediatrics
have shown no advantage of autologous HSCT compared to
chemotherapy alone and the majority of clinical trials have
demonstrated a consistent advantage for allogeneic HSCT
in terms of disease-free survival, but not always for OS (3, 6,
20-22). In our study period, allogeneic HSCT was recom-
mended to all patients in first remission with HLA-matched
familial or unrelated donors and autologous HSCT was per-
formed for patients without an available donor. The patients
who were not candidates for HSCT received intensive chemo-
therapy according to the institutional principle. Therefore,
our study is not a prospective randomized trial comparing
chemotherapy with HSCT and our results may have a selec-
tion bias in survival analysis. For this reason, our results do
not suggest the superiority of transplantation over intensive
chemotherapy but the comparable outcomes of IDA plus
BHAC and 6-TG versus idarubicin plus cytarabine-based
regimen in childhood de novo AML regardless of post-induc-
tion therapy.
The cytogenetic aberrations in our study show a high pro-
portion of children with t(8;21) compared to other studies
(2-6). In our pediatric population, the children with favorable
karyotypes such as t(8;21) or inv(16) appear to show a bet-
ter outcome than those with an unfavorable kayrotype in both
the BHAC and cytarabine group. However, recent reports
suggest that t(8;21) and inv(16) AMLs seem to be distinct
clinical entities and should be stratified and reported sepa-
rately when considering race, secondary cytogenetic abnor-
malities (23, 24). Karyotype markers with unfavorable impli-
cations also have been identified, such as -5/del(5q) and -7/
del(7q) (3). In our data, the patients with -7/del(7q) show a
very poor prognosis compared to the reported figure (21).
Only two patients had -5/del(5q), a rare cytogenetic abnor-
mality in children, so it appears difficult to draw any conclu-
sion. This issue needs to be elucidated further in the future,
as well as the other prognostic implications such as FLT3 inter-
nal tandem duplications (FLT3-ITDs) (25). 
This study is limited by its retrospective nature. Patients
are not equally randomized into the BHAC group and cytara-
bine group in induction or post-remission therapy at each
institution. There is a little heterogeneity in the induction
regimen and post-remission therapy in terms of administra-
tion schedule of cytarabine, addition of etoposide, and dif-
ferent consolidation schedule. However, the main point of
our investigation is that BHAC shows a similar efficacy com-
pared to cytarabine in combination chemotherapy in view
of induction response and long term survival. Another limi-
tation is that the information for adverse events during induc-
tion therapy is not enough to compare the two groups in terms
of regimen-related toxicity. Since childhood AML is a rare
disease, further studies with a prospective, randomized, mul-
tiinstitutional cohort are required to validate the results of
our study and additional studies about risk-directed therapy
including post-remission intensive chemotherapy and HSCT
are warranted. 
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